207 related articles for article (PubMed ID: 16717104)
1. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli.
DeFrees S; Wang ZG; Xing R; Scott AE; Wang J; Zopf D; Gouty DL; Sjoberg ER; Panneerselvam K; Brinkman-Van der Linden EC; Bayer RJ; Tarp MA; Clausen H
Glycobiology; 2006 Sep; 16(9):833-43. PubMed ID: 16717104
[TBL] [Abstract][Full Text] [Related]
2. PEGylated murine Granulocyte-macrophage colony-stimulating factor: production, purification, and characterization.
Sainathan SK; Tu L; Bishnupuri KS; Han M; Li A; Newberry RD; McDonald KG; Crimmins DL; Houchen C; Anant S; Dieckgraefe BK
Protein Expr Purif; 2005 Dec; 44(2):94-103. PubMed ID: 16213750
[TBL] [Abstract][Full Text] [Related]
3. Site-directed enzymatic PEGylation of the human granulocyte colony-stimulating factor.
Maullu C; Raimondo D; Caboi F; Giorgetti A; Sergi M; Valentini M; Tonon G; Tramontano A
FEBS J; 2009 Nov; 276(22):6741-50. PubMed ID: 19843182
[TBL] [Abstract][Full Text] [Related]
4. Reproducible preparation and effective separation of PEGylated recombinant human granulocyte colony-stimulating factor with novel "PEG-pellet" PEGylation mode and ion-exchange chromatography.
Yun Q; Yang RE; Chen T; Bi J; Ma G; Su Z
J Biotechnol; 2005 Jul; 118(1):67-74. PubMed ID: 15904987
[TBL] [Abstract][Full Text] [Related]
5. Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge.
Balan S; Choi JW; Godwin A; Teo I; Laborde CM; Heidelberger S; Zloh M; Shaunak S; Brocchini S
Bioconjug Chem; 2007; 18(1):61-76. PubMed ID: 17226958
[TBL] [Abstract][Full Text] [Related]
6. Site-specific incorporation of the mucin-type N-acetylgalactosamine-alpha-O-threonine into protein in Escherichia coli.
Xu R; Hanson SR; Zhang Z; Yang YY; Schultz PG; Wong CH
J Am Chem Soc; 2004 Dec; 126(48):15654-5. PubMed ID: 15571382
[TBL] [Abstract][Full Text] [Related]
7. C-terminal site-specific PEGylation of a truncated thrombomodulin mutant with retention of full bioactivity.
Cazalis CS; Haller CA; Sease-Cargo L; Chaikof EL
Bioconjug Chem; 2004; 15(5):1005-9. PubMed ID: 15366953
[TBL] [Abstract][Full Text] [Related]
8. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
[TBL] [Abstract][Full Text] [Related]
9. Protein carboxyl amidation increases the potential extent of protein polyethylene glycol conjugation.
Li S; Yang Z; Sun X; Tan Y; Yagi S; Hoffman RM
Anal Biochem; 2004 Jul; 330(2):264-71. PubMed ID: 15203332
[TBL] [Abstract][Full Text] [Related]
10. Site-specific modification of recombinant proteins: a novel platform for modifying glycoproteins expressed in E. coli.
Henderson GE; Isett KD; Gerngross TU
Bioconjug Chem; 2011 May; 22(5):903-12. PubMed ID: 21395336
[TBL] [Abstract][Full Text] [Related]
11. Application of microchip CGE for the analysis of PEG-modified recombinant human granulocyte-colony stimulating factors.
Park EJ; Lee KS; Lee KC; Na DH
Electrophoresis; 2010 Nov; 31(22):3771-4. PubMed ID: 20945411
[TBL] [Abstract][Full Text] [Related]
12. Site-specific pegylation of G-CSF by reversible denaturation.
Veronese FM; Mero A; Caboi F; Sergi M; Marongiu C; Pasut G
Bioconjug Chem; 2007; 18(6):1824-30. PubMed ID: 17941684
[TBL] [Abstract][Full Text] [Related]
13. A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentration.
Krinner EM; Hepp J; Hoffmann P; Bruckmaier S; Petersen L; Petsch S; Parr L; Schuster I; Mangold S; Lorenczewski G; Lutterbüse P; Buziol S; Hochheim I; Volkland J; Mølhøj M; Sriskandarajah M; Strasser M; Itin C; Wolf A; Basu A; Yang K; Filpula D; Sørensen P; Kufer P; Baeuerle P; Raum T
Protein Eng Des Sel; 2006 Oct; 19(10):461-70. PubMed ID: 16868004
[TBL] [Abstract][Full Text] [Related]
14. PEGylation of native disulfide bonds in proteins.
Brocchini S; Balan S; Godwin A; Choi JW; Zloh M; Shaunak S
Nat Protoc; 2006; 1(5):2241-52. PubMed ID: 17406463
[TBL] [Abstract][Full Text] [Related]
15. Novel polyethylene glycol derivative suitable for the preparation of mono-PEGylated protein.
Yun Q; Chen T; Zhang G; Bi J; Ma G; Su Z
Biotechnol Lett; 2005 Feb; 27(3):213-7. PubMed ID: 15717132
[TBL] [Abstract][Full Text] [Related]
16. The uses and properties of PEG-linked proteins.
Delgado C; Francis GE; Fisher D
Crit Rev Ther Drug Carrier Syst; 1992; 9(3-4):249-304. PubMed ID: 1458545
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol.
Katre NV
J Immunol; 1990 Jan; 144(1):209-13. PubMed ID: 2295792
[TBL] [Abstract][Full Text] [Related]
18. Site-directed pegylation of recombinant interleukin-2 at its glycosylation site.
Goodson RJ; Katre NV
Biotechnology (N Y); 1990 Apr; 8(4):343-6. PubMed ID: 1366535
[TBL] [Abstract][Full Text] [Related]
19. Transglutaminase-mediated PEGylation of proteins: direct identification of the sites of protein modification by mass spectrometry using a novel monodisperse PEG.
Mero A; Spolaore B; Veronese FM; Fontana A
Bioconjug Chem; 2009 Feb; 20(2):384-9. PubMed ID: 19186937
[TBL] [Abstract][Full Text] [Related]
20. Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase.
Fontana A; Spolaore B; Mero A; Veronese FM
Adv Drug Deliv Rev; 2008 Jan; 60(1):13-28. PubMed ID: 17916398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
